Skip to main content
Download PDF

Effects of delta-opioid receptor agonist pretreatment on the cardiotoxicity of bupivacaine in rats

BMC Anesthesiology volume 22, Article number: 19 (2022) Cite this article

Abstract

Background

Delta-opioid receptor is widely expressed in human and rodent hearts, and has been proved to protect cardiomyocytes against ischemia/reperfusion and heart failure. The antagonist of delta-opioid receptor could block the rescue effect of lipid emulsion against local anesthetic cardiotoxicity. However, no evidence is available for the direct effect of delta-opioid-receptor agonists on the cardiotoxicity of local anesthetics.

Methods

Anesthetized Sprague Dawley rats were divided into five groups. Group NS received 2 ml·kg−1·min−1 normal saline, group LE received 2 ml·kg−1·min−1 30% lipid emulsion and group BW received 0.1, 1.0, or 5.0 mg/kg BW373U86, a delta-opioid-receptor agonist, for 5 min. Then 0.5% bupivacaine was infused intravenously at a rate of 3.0 mg·kg−1·min−1 until asystole. The time of arrhythmia, 50% mean arterial pressure-, 50% heart rate-reduction and asystole were recorded, and the dose of bupivacaine at each time point was calculated.

Results

All three different doses of BW373U86 did not affect the arrhythmia, 50% mean arterial pressure-reduction, 50% heart rate-reduction and asystole dose of bupivacaine compared with group NS. 30% LE significantly increased the bupivacaine threshold of 50% mean arterial pressure-reduction (17.9 [15.4–20.7] versus 7.2 [5.9–8.7], p = 0.018), 50% heart rate-reduction (18.7 ± 4.2 versus 8.8 ± 1.7, p < 0.001) and asystole (26.5 [21.0–29.1] versus 11.3 [10.7–13.4], p = 0.008) compared with group NS. There was no difference between group LE and group NS in the arrhythmia dose of bupivacaine (9.9 [8.9–11.7] versus 5.6 [4.5–7.0], p = 0.060).

Conclusions

Our data show that BW373U86 does not affect the cardiotoxicity of bupivacaine compared with NS control in rats. 30% LE pretreatment protects the myocardium against bupivacaine-induced cardiotoxicity.

Peer Review reports

Background

With the development of enhanced recovery after surgery (ERAS) and labor analgesia, peripheral nerve block and epidural anesthesia become more and more important for their indispensable role in comfort medicine. Local anesthetic systemic toxicity (LAST) is the adverse effect of regional anesthesia due to unexpected local anesthetics absorbed or infused into the bloodstream [1]. The main symptoms of LAST are central nervous systemic toxicity and cardiotoxicity, of which cardiotoxicity is life-threatening [2]. Lipid emulsion (LE) has been reported to resuscitate LAST successfully in animal experiments and clinical practices [3, 4]. A widely accepted theory of LE rescue is that lipophilic local anesthetics are absorbed into the lipid phase of plasma from tissues [5]. Thus, the toxicity of local anesthetics to tissue is mitigated by LE. However, in 2015, Partownavid et al. [6] reported that LE fails to rescue rats against bupivacaine-induced cardiotoxicity when a high-dose of delta-opioid receptor (DOR) antagonist was preconditioned. This indicates that DOR is involved in the LE rescue of LAST.

DOR is widely expressed in human and rodent cardiomyocytes. And the expression of DOR increases in response to heart failure, hypoxia, aging, and other physical or pathological stimuli [7]. Many studies have proved that agonists of DOR can protect the myocardium against ischemia/reperfusion and heart failure [8,9,10,11]. However, no evidence is available concerning the direct effect of DOR agonists on the cardiotoxicity of local anesthetics.

We hypothesized that the agonist of DOR can protect the heart against bupivacaine-induced cardiotoxicity in rats. The purpose of this study is to investigate whether DOR agonist has protective effects on bupivacaine cardiotoxicity. We pretreated anesthetized Sprague Dawley rats with normal saline, lipid emulsion, and three different doses of BW373U86 (0.1, 1.0, 5.0 mg/kg), a DOR agonist, before bupivacaine infusion. Our primary outcome is the asystole dose of bupivacaine in rats. Our secondary outcomes are the doses of bupivacaine when arrhythmia, 50% mean arterial pressure (MAP)-reduction, and 50% heart rate (HR)-reduction occur.

Methods

Animals

The animal study was reviewed and approved by the Animal Care and Use Committee of Fudan University on 16 March 2021 (ethic approval ID: 20,210,316–001) and performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. All animal experiments were reported in compliance with the ARRIVE guidelines. Thirty male Sprague Dawley rats aged 5–6 weeks were purchased from Shanghai JieSiJie Laboratory Animals Co. Ltd (Shanghai, China) and housed in a standard environment (23 ± 1℃, 50% relative humidity and 12-h day/night cycle) for more than 7 days before experiments.

Anesthesia and Monitoring

This model of LAST has been used by many previous studies [2, 4, 6]. Rats (240–280 g) fasted for 12 h before experiments with free access to water. The animals were anesthetized with 350 mg/kg chloral hydrate intraperitoneally. Then they were nasally ventilated using a rodent animal ventilator (ALC-V8, Shanghai Alcott biotech CO.LTD, Shanghai, China). The ventilator settings are as follows: respiratory rate 60 breaths/min, tidal volume 2 ml/100 g, and inspiratory to expiratory ratio 1:2. Sevoflurane (1–2%) in 30% O2 was started before the median incision in the neck was made [12]. The right jugular vein and the left carotid artery were intubated with a silastic tube (external diameter × internal diameter = 1.0 × 0.5 mm). Then, rats were intubated by tracheotomy with a 16G angio-catheter. Last, three electrode needles were inserted subcutaneously in both forelimbs and left hindlimb to measure Electrocardiogram (ECG). ECG and invasive arterial blood pressure were constantly recorded with a monitor. After all invasive procedures were finished, sevoflurane was discontinued, the time of surgery (time from neck incision to the end of invasive procedures) was recorded. Rats were allowed to stabilize for 10-15 min. At the end of the stabilization period, HR and MAP were recorded as baseline values. Rectal temperature was maintained at 37 ± 1℃ by a heater throughout the experiment.

Experimental Procedures

Thirty rats were randomly assigned to five groups (n = 6 for each) according to random numbers. All liquids were infused through the right jugular vein using an infusion pump (B. Braun Medical Co., Ltd, Suzhou, China). Group NS received 2 ml·kg−1·min−1 normal saline for 5 min; group LE received 2 ml·kg−1·min−1 30% lipid emulsion (80PE018, Sino-Swed Pharmaceutical Corp. Ltd, Jiangsu, China) for 5 min; and BW groups received 0.1, 1.0 or 5.0 mg/kg (diluted in 10 ml/kg normal saline) BW373U86 (Cat. No. 1663, Tocris Bioscience, USA) for 5 min. The low, median and high doses of BW373U86 were set as 0.1, 1.0, and 5.0 mg/kg according to the previous study [13,14,15,16]. After a 1-min wait, which was the time of changing syringes and resetting the velocity of the infusion pump, 0.5% bupivacaine (090,809, Shanghai Harvest Pharmaceutical CO., LTD, Shanghai, China) at a rate of 3.0 mg·kg−1·min−1 was started to infuse until asystole occurs. Rats were anesthetized with 350 mg/kg chloral hydrate. Thus, animals went into cardiac arrest gradually under anesthesia at the end of the study.

The following toxic endpoints were recorded by an observer unaware of the grouping, and the doses of bupivacaine at each endpoint were calculated: the first arrhythmia, defined as the appearance of cardiac rhythm disturbance on the ECG accompanied by an abnormal pulsation on the arterial pressure trace; 50% MAP-reduction, defined as the MAP of 50% baseline value; 50% HR-reduction, defined as the HR of 50% baseline value; and asystole, defined as the lack of recognizable beat on the ECG for 10 s after the appearance of the last systole. These observed indexes were decided following previous studies [4, 9, 17].

Statistical Analysis

The software program of Power and Sample Size (PASS15.0.5, NCSS Inc, Kaysville, UT) was used to calculate the sample size [2]. Based on the preliminary experiments of 0.5% bupivacaine at a rate of 3.0 mg·kg−1·min−1. The mean asystole doses of group NS, LE, 0.1, 1.0, and 5.0 mg/kg BW are 12.1 25.5 14.4 13.2 12.9, and the standard errors are 2.3 5.0 3.1 4.0 4.0 respectively. Power was set at 0.90; significance was set at 0.05, and one-way analysis of variance (ANOVA) was used. The effect size of 5 was estimated. Considering the loss potential and errors, 6 rats for each group were decided.

Data were analyzed with SPSS (version 20.0; Chicago, Illinois, USA) for Windows by a statistician who is blinded to the grouping. The Shapiro–Wilk test was used to test for normal distribution. Normal-distributed measures and abnormal-distributed measures were presented as mean ± standard deviation and median [interquartile range] respectively. Normally distributed measures were compared using a one-way ANOVA model and abnormally distributed measures were compared using the Kruskal–Wallis test. The individual pairwise mean comparisons were adjusted with the Tukey studentized range criterion or Dunn’s test to account for multiple comparisons. The family-wise significance for all tests is set at p < 0.05.

Results

The timeline of the experiment is shown in Fig. 1. The baseline values of weight, MAP, HR and invasive surgery time are presented in Table 1, and no difference was observed among these five groups.

Fig. 1
figure 1

Timeline of the experiment. At the baseline, rats were infused with 2 ml·kg−1··min−1 normal saline, 30% lipid emulsion, 0.1, 1.0, or 5.0 mg/kg BW373U86, the agonist of delta-opioid receptor for 5 min. After waiting 1 min to change the syringe and the speed of the infusion pump, 0.5% bupivacaine 3.0 mg·kg−1··min−1 was started to infuse until asystole occurs

Full size image
Table 1 Baseline values
Full size table

All three doses of BW373U86 (0.1, 1.0, and 5.0 mg/kg) had no effect on the bupivacaine threshold of arrhythmia, 50% MAP-reduction, 50% HR-reduction, or asystole compared with NS control (Fig. 2). 30% LE increased the bupivacaine threshold of 50% MAP-reduction (17.9 [15.4–20.7] versus 7.2 [5.9–8.7], p = 0.018), 50% HR-reduction (18.7 ± 4.2 versus 8.8 ± 1.7, p < 0.001) and asystole (26.5 [21.0–29.1] versus 11.3 [10.7–13.4], p = 0.008) compared with group NS. There is no difference between group LE and group NS on the arrhythmia dose of bupivacaine (9.9 [8.9–11.7] versus 5.6 [4.5–7.0], p = 0.060).

Fig. 2
figure 2

The bupivacaine threshold of different cardiotoxic endpoints: a arrhythmia; b 50% MAP-reduction; c 50% HR-reduction; d asystole. Differences were found between group NS and LE in the bupivacaine dose of 50% MAP-reduction, 50% HR-reduction, and asystole. Abbreviations: NS normal saline, LE lipid emulsion, BW BW373U86, the agonist of delta-opioid receptor, MAP mean arterial pressure, HR heart rate.*p < 0.05, **p < 0.01, ***p < 0.001

Full size image

Discussion

The cardioprotective effects of DOR in ischemia/reperfusion and heart failure have long been highlighted in both in vivo and in vitro studies [8, 10, 18, 19], while the effect of DOR agonist on the cardiotoxicity of local anesthetics has never been explored before. Our study firstly investigated the effect of DOR agonist on the cardiotoxicity of bupivacaine in rats, however, we didn’t observe any positive effect.

DOR is widely expressed in human and rodent myocardium and has been proved to involve in the cardioprotective and neuroprotective procedures in myocardial ischemia/reperfusion [8, 9, 13, 19, 20]. The mechanisms of DOR protective effects on the myocardium include triggering PKC, ERK1/2, Akt/PIK3, and other pathways. These activated pathways may confer protection through regulating anti-apoptotic and autophagy elements, releasing NO, inhibiting Ca2+ overload, phosphorylating GSK3β, inhibiting mitochondrial permeability transition pore (mPTP) open [21], and activating mitochondrial KATP [7, 22], of which mitochondrial function is closely involved. Both Furado et al. [21] and Bell et al. [19] reported that the contraction of human atrial trabeculae after ischemia/reperfusion is significantly increased with Delta 2 opioid D-Ala2-Leu5 enkephalin (DADLE, a DOR agonist) treatment. And the protective effect of DADLE is mediated by both the mPTP opener and mitochondrial KATP channel (mKATP).

It has been proved that bupivacaine exerts an adverse effect on the myocardium by inhibiting ion channels open (including sodium, potassium, and calcium channels) and disturbing mitochondrial energy metabolism [23, 24]. Chen Y et al. [25] reported that ropivacaine injuries human neuron SH-5Y5Y through opening mPTP, decreasing ATP production and inducing other mitochondrial dysfunctions. Thus, we hypothesized that DOR may protect the myocardium against bupivacaine by modulating mitochondrial function. However, we didn’t observe any protective effects of DOR on the cardiotoxicity of bupivacaine in rats.

We chose 0.1, 1.0, and 5.0 mg/kg BW373U86, which is the low, median, and high doses of BW that have been proved to activate DOR in rats [13,14,15,16]. Therefore, we think it’s sufficient to conclude that BW does not affect the cardiotoxicity of bupivacaine. This result seems contradictory to that of Partownavid et al. [6]. Partownavid et al. reported that DOR antagonists can abolish the therapeutic effect of LE against bupivacaine toxicity, which indicates that LE may exert protective effects by activating DOR. The reason for the difference may be due to the complex mechanism of LE rescuing LAST. DOR may only play an important role in it. However, it’s not enough to ameliorate the toxicity of local anesthetics by activating DOR alone.

Unlike the 20% LE that is used mostly, we used 30% LE. Because 30% LE has been proved to exert cardioprotective effects against LAST as well [4], and the ratio of the main effective ingredients of 30% LE to that of 20% LE is 2:3. Thus we chose 2 ml·kg−1·min−1 30% LE following the dose of LE used by Weinberg and other researchers [4, 26, 27].

The median doses of bupivacaine producing asystole in group NS and group LE of our study are 11.3 mg/kg and 26.5 mg/kg respectively. Both the two doses are lower than that of the study of Weinberg (group NS 17.7 mg/kg and group LE 49.7 mg/kg) [4]. We think this is mainly because we discontinued sevoflurane while Weinberg et al. did not. And inhale anesthetics, like sevoflurane and isoflurane, can prolong the death time of local anesthetics [28, 29]. Because inhale anesthetics exert cardioprotective effects against LAST, thus we stopped sevoflurane as soon as finishing the invasive procedure and waited for 10–15 min to allow rats to exhale sevoflurane so that the result is more credible.

There are some limitations of our study. First, we just observed a phenomenon. This is mainly because the negative outcome limits further investigations on the mechanism. Second, we only studied the preventative effect without the resuscitative effect of DOR agonist on LAST. For lipid emulsion has been considered as the golden standard for the rescue of LAST, and we aimed to look for one drug that may help to prevent the cardiotoxicity of local anesthetics. Third, we didn’t mirror expired CO2 concentration in this experiment, which may affect cardiac function. However, most of the literature we referred didn’t mirror expired CO2 concentration, too. And the ventilator settings of our experiment are the same as those of others.

Conclusions

Our study demonstrates that BW373U86 does not affect the cardiotoxicity of bupivacaine in rats compared with normal saline control. 30% lipid emulsion can protect the myocardium against bupivacaine-induced cardiotoxicity.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Abbreviations

NS:

Normal saline

LE:

Lipid emulsion

BW:

BW373U86

ERAS:

Enhanced recovery after surgery

MAP:

Mean arterial pressure

HR:

Heart rate

LAST:

Local anesthetic systemic toxicity

ECG:

Electrocardiogram

DADLE:

Delta 2 opioid D-Ala2-Leu5 enkephalin

mPTP:

mitochondrial permeability transition pore

References

  1. Dickerson DM, Apfelbaum JL. Local anesthetic systemic toxicity. Aesthet Surg J. 2014;34(7):1111–9.

    Article  Google Scholar 

  2. Liu L, Jin Z, Cai X, Xia Y, Zhang M, Papadimos TJ, Xu X, Shi K. Comparative Regimens of Lipid Rescue From Bupivacaine-Induced Asystole in a Rat Model. Anesth Analg. 2019;128(2):256–63.

    Article  CAS  Google Scholar 

  3. Ok SH, Hong JM, Lee SH, Sohn JT. Lipid Emulsion for Treating Local Anesthetic Systemic Toxicity. Int J Med Sci. 2018;15(7):713–22.

    Article  CAS  Google Scholar 

  4. Weinberg GL, VadeBoncouer T, Ramaraju GA, Garcia-Amaro MF, Cwik MJ. Pretreatment or resuscitation with a lipid infusion shifts the dose-response to bupivacaine-induced asystole in rats. Anesthsiology. 1998;88(4):1071–5.

    Article  CAS  Google Scholar 

  5. Mather LE, Copeland SE. MVetClinStud, Ladd LA: Acute toxicity of local anesthetics underlying pharmacokinetic and pharmacodynamic concepts. Reg Anesth Pain Med. 2005;30(6):553–66.

    CAS  PubMed  Google Scholar 

  6. Partownavid P, Sharma S, Li J, Umar S, Rahman S, Eghbali M. Involvement of Opioid Receptors in the Lipid Rescue of Bupivacaine-Induced Cardiotoxicity. Anesth Analg. 2015;121(2):340–7.

    Article  CAS  Google Scholar 

  7. See Hoe L, Patel HH, Peart JN. Delta Opioid Receptors and Cardioprotection. Handb Exp Pharmacol. 2018;247:301–34.

    Article  Google Scholar 

  8. Patel HH, Hsu A, Moore J, Gross GJ. BW373U86, a delta opioid agonist, partially mediates delayed cardioprotection via a free radical mechanism that is independent of opioid receptor stimulation. J Mol Cell Cardiol. 2001;33(8):1455–65.

    Article  CAS  Google Scholar 

  9. Pan L, Zhang Y, He Y, Chen Z, Wang S, Xia Y, Papadimos TJ, Lin W, Xu X. Dexmedetomidine elevates the lethal dose threshold of bupivacaine in rats: A dosing study. Hum Exp Toxicol. 2020;39(3):365–73.

    Article  CAS  Google Scholar 

  10. Treskatsch S, Feldheiser A, Shaqura M, Dehe L, Habazettl H, Ropke TK, Shakibaei M, Schafer M, Spies CD, Mousa SA. Cellular localization and adaptive changes of the cardiac delta opioid receptor system in an experimental model of heart failure in rats. Heart Vessels. 2016;31(2):241–50.

    Article  Google Scholar 

  11. Fu D, Liu H, Li S, Chen L, Yao J. Antioxidative and Antiapoptotic Effects of Delta-Opioid Peptide [D-Ala(2), D-Leu(5)] Enkephalin on Spinal Cord Ischemia-Reperfusion Injury in Rabbits. Front Neurosci. 2017;11:603.

    Article  Google Scholar 

  12. Luo M, Yun X, Chen C, Bao N, Feng X, Pan L, Jin Z, Wu C, Wang X, Papadimos TJ, et al. Giving Priority to Lipid Administration Can Reduce Lung Injury Caused by Epinephrine in Bupivacaine-Induced Cardiac Depression. Reg Anesth Pain Med. 2016;41(4):469–76.

    Article  CAS  Google Scholar 

  13. Yang L, Zhao X, Sun M, Sun X, Yao L, Yu D, Ding Q, Gao C, Chai W. Delta opioid receptor agonist BW373U86 attenuates post-resuscitation brain injury in a rat model of asphyxial cardiac arrest. Resuscitation. 2014;85(2):299–305.

    Article  CAS  Google Scholar 

  14. Shinmura K, Nagai M, Tamaki K, Bolli R. Gender and aging do not impair opioid-induced late preconditioning in rats. Basic Res Cardiol. 2004;99(1):46–55.

    Article  CAS  Google Scholar 

  15. Patel HH, Ludwig LM, Fryer RM, Hsu AK, Warltier DC, Gross GJ. Delta opioid agonists and volatile anesthetics facilitate cardioprotection via potentiation of K(ATP) channel opening. Faseb j. 2002;16(11):1468–70.

    Article  CAS  Google Scholar 

  16. Patel HH, Hsu AK, Gross GJ. COX-2 and iNOS in opioid-induced delayed cardioprotection in the intact rat. Life Sci. 2004;75(2):129–40.

    Article  CAS  Google Scholar 

  17. Piskin O, Ayoglu H. Effects of Remifentanil Pretreatment on Bupivacaine Cardiotoxicity in Rats. Cardiovasc Toxicol. 2018;18(1):56–62.

    Article  CAS  Google Scholar 

  18. Funcke S, Werner TR, Hein M, Ulmer BM, Hansen A, Eschenhagen T, Hirt MN. Effects of the Delta Opioid Receptor Agonist DADLE in a Novel Hypoxia-Reoxygenation Model on Human and Rat-Engineered Heart Tissue: A Pilot Study. Biomolecules. 2020;10(9):1309.

    Article  CAS  Google Scholar 

  19. Bell SP, Sack MN, Patel A, Opie LH, Yellon DM. Delta opioid receptor stimulation mimics ischemic preconditioning in human heart muscle. J Am Coll Cardiol. 2000;36(7):2296–302.

    Article  CAS  Google Scholar 

  20. Maslov LN, Oeltgen PR, Lishmanov YB, Brown SA, Barzakh EI, Krylatov AV, Pei JM. Activation of peripheral delta opioid receptors increases cardiac tolerance to arrhythmogenic effect of ischemia/reperfusion. Acad Emerg Med. 2014;21(1):31–9.

    Article  Google Scholar 

  21. Fuardo M, Lemoine S, Lo Coco C, Hanouz JL, Massetti M. [D-Ala2, D-Leu5]-enkephalin (DADLE) and morphine-induced postconditioning by inhibition of mitochondrial permeability transition pore, in human myocardium. Exp Biol Med (Maywood). 2013;238(4):426–32.

    Article  Google Scholar 

  22. Lv MR, Li B, Wang MG, Meng FG, Yu JJ, Guo F, Li Y. Activation of the PI3K-Akt pathway promotes neuroprotection of the delta-opioid receptor agonist against cerebral ischemia-reperfusion injury in rat models. Biomed Pharmacother. 2017;93:230–7.

    Article  CAS  Google Scholar 

  23. Sztark F, Malgat M, Dabadie P, Mazat JP. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology. 1998;88(5):1340–9.

    Article  CAS  Google Scholar 

  24. Sztark F, Tueux O, Erny P, Dabadie P, Mazat JP. Effects of bupivacaine on cellular oxygen consumption and adenine nucleotide metabolism. Anesth Analg. 1994;78(2):335–9.

    Article  CAS  Google Scholar 

  25. Chen Y, Yan L, Zhang Y, Yang X. The role of DRP1 in ropivacaine-induced mitochondrial dysfunction and neurotoxicity. Artif Cells Nanomed Biotechnol. 2019;47(1):1788–96.

    Article  CAS  Google Scholar 

  26. Oda Y, Ikeda Y. Effect of lipid emulsion on the central nervous system and cardiac toxicity of bupivacaine and levobupivacaine in awake rats. J Anesth. 2013;27(4):500–4.

    Article  Google Scholar 

  27. Hanci V, Karakaya K, Yurtlu S, Hakimoğlu S, Can M, Ayoğlu H, Erdoğan G, Okyay RD, Turan IO. Effects of dexmedetomidine pretreatment on bupivacaine cardiotoxicity in rats. Reg Anesth Pain Med. 2009;34(6):565–8.

    Article  CAS  Google Scholar 

  28. Fukuda H, Hirabayashi Y, Shimizu R, Saitoh K, Mitsuhata H. Sevoflurane is equivalent to isoflurane for attenuating bupivacaine-induced arrhythmias and seizures in rats. Anesth Analg. 1996;83(3):570–3.

    Article  CAS  Google Scholar 

  29. Tanaka K, Ludwig LM, Kersten JR, Pagel PS, Warltier DC. Mechanisms of cardioprotection by volatile anesthetics. Anesthesiology. 2004;100(3):707–21.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Dr. Yanqin Gao for providing the laboratory and rodent ventilator for this study. We are also grateful to Di Chen, Yiying Zhang, and Wei Li for their technical support and helpful discussion.

Funding

No funding is declared

Author information

Authors and Affiliations

  1. Department of Anesthesia, Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China

    Chenran Wang, Shen Sun, Jing Jiao & Shaoqiang Huang

  2. Division of Epidemiology, Biostatistics and Environmental Health, Scholl of Health, University of Memphis, Memphis, USA

    Xinhua Yu

Authors
  1. Chenran Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shen Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xinhua Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shaoqiang Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Methodology and Original draft preparation: CW; Methodology and Review: SS and JJ; Statistical analysis and Review: XY; Supervision, Resource, and Review: SH. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Shaoqiang Huang.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Animal Care and Use Committee of Fudan University on 16 March 2021 (ethic approval ID: 20210316–001) and performed according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The study was carried out in compliance with the ARRIVE guidelines.

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, C., Sun, S., Jiao, J. et al. Effects of delta-opioid receptor agonist pretreatment on the cardiotoxicity of bupivacaine in rats. BMC Anesthesiol 22, 19 (2022). https://doi.org/10.1186/s12871-022-01568-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12871-022-01568-x

Keywords

BMC Anesthesiology

ISSN: 1471-2253

Contact us